AI Article Synopsis

  • * Among patients on 1st or 2nd generation TKIs, those with a higher PLR (≥ 180) had a significantly shorter median progression-free survival (PFS) compared to those with a lower PLR (< 180).
  • * The findings suggest that while PLR is a useful predictor for traditional TKIs, it may be less relevant for the third generation TKI, osimertinib, which showed different impacts on blood cell counts and patient outcomes.

Article Abstract

Introduction: The predictive utility of laboratory markers in patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations treated with tyrosine kinase inhibitors (TKIs) is an ongoing area of research. The predictability of the platelet-lymphocyte ratio (PLR) on survival outcomes depending on the generation of EGFR TKI is undetermined.

Methods: 151 patients treated with EGFR TKIs in Los Angeles were grouped according to generation of TKI. Differences in progression free survival (PFS) by stratification by PLR was determined using Kaplan-Meier analysis. Differences in median change in laboratory markers by generation of TKI was analyzed using Mann-Whitney tests. Cox Hazard Regression was used to perform multivariate analysis.

Results: Median PFS of those managed with 1st or 2nd generation TKIs was significantly lower in patients with a PLR ≥ 180 (10.5 months) compared to those with PLR < 180 (16.6 months, p = 0.0163). Median PFS was comparable in those treated with osimertinib regardless of PLR. Patients managed with osimertinib had a significant decrease in absolute lymphocyte count (ALC) at 6 weeks and in platelets at 6 weeks and 3 months compared to those managed with 1st or 2nd generation TKIs.

Discussion: The predictive value of PLR was more apparent in patients treated with 1st or 2nd generation TKIs compared to those treated with osimertinib. Third generation EGFR TKIs may be more efficacious in treating patients with laboratory findings previously shown to predict poor survival. The significant changes in peripheral cell counts suggest variable tumor microenvironment changes dependent on the generation of TKI received.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11582238PMC
http://dx.doi.org/10.1007/s12672-024-01606-9DOI Listing

Publication Analysis

Top Keywords

platelet-lymphocyte ratio
8
non-small cell
8
cell lung
8
lung cancer
8
patients treated
8
treated tyrosine
8
tyrosine kinase
8
kinase inhibitors
8
laboratory markers
8
generation tki
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!